Vildagliptin For Type II Diabetes Can Be Combined With All Other Diabetes Drugs
This article was originally published in PharmAsia News
Partial changes to the efficacy and indication of Novartis Pharmaceuticals’ DPP-4 inhibitor drug Equa (vildagliptin) have been approved, the company announced on Feb. 28.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.